The largest trial to examine the impact of colchicine in acute myocardial infarction (MI)—CLEAR SYNERGY (OASIS 9)—found that both acute and long-term colchicine use did not reduce cardiovascular death, myocardial infarction, stroke, or ischemia-driven revascularisation.
At a median follow-up of three years, the composite of cardiovascular death, recurrent MI, stroke, or ischaemia driven revascularisation was not significantly different between the colchicine and placebo groups [9.1 vs. 9.3%, HR 0.99, 95% CI (0.85-1.16), p=0.93]. In addition, there were no significant differences in any of the individual components of the composite endpoint.
“We designed this trial to provide reliable evidence of the effect of routine colchicine in acute myocardial infarction on clinically important outcomes,” said Sanjit S Jolly (McMaster University and Hamilton Health Sciences, Hamilton, Canada) principal investigator of the study, who reported the findings at TCT 2024 (27–30 October, Washington, DC, USA).
“As the largest trial to date on this subject (649 outcome events), with significantly more events than previous studies, colchicine did not provide a significant benefit and its role in long-term post myocardial infarction use is uncertain.”
